Baikati Kiran, Le Duong L, Jabbour Ibrahim I, Singhal Shashideep, Anand Sury
Department of Gastroenterology, The Brooklyn Hospital Center, Brooklyn, NY.
Am J Ther. 2014 Jan-Feb;21(1):43-51. doi: 10.1097/MJT.0b013e318228319e.
Hepatic hydrothorax is defined as a pleural effusion in patients with liver cirrhosis in the absence of cardiopulmonary disease. The estimated prevalence among patients with liver cirrhosis is approximately 5-6%. The pathophysiology involves the passage of ascitic fluid from the peritoneal cavity to the pleural space through diaphragmatic defects. The diagnosis is made from clinical presentation and confirmed by diagnostic thoracentesis with pleural fluid analysis. The initial medical management is sodium restriction and diuretics, but liver transplantation provides the only definitive therapy. For patients who are not transplant candidates and those who await organ availability, other therapeutic modalities that are to be considered include transjugular intrahepatic portosystemic shunt placement, videoassisted thoracoscopic surgery repair, pleurodesis, and vasoconstrictors (eg, octreotide and terlipressin). The primary therapeutic goals are to reduce ascitic fluid production and improve symptoms to bridge the time for liver transplantation.
肝性胸水被定义为肝硬化患者在无心肺疾病情况下出现的胸腔积液。肝硬化患者中的估计患病率约为5% - 6%。其病理生理学涉及腹水通过膈肌缺损从腹腔进入胸腔。诊断基于临床表现,并通过胸腔穿刺术及胸水分析得以证实。初始药物治疗为限钠和使用利尿剂,但肝移植是唯一的确定性治疗方法。对于不适合肝移植的患者以及等待器官可供移植的患者,其他可考虑的治疗方式包括经颈静脉肝内门体分流术、电视辅助胸腔镜手术修复、胸膜固定术和血管收缩剂(如奥曲肽和特利加压素)。主要治疗目标是减少腹水生成并改善症状,以度过等待肝移植的时间。